A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Jul 2019
Price : $35 *
At a glance
- Drugs Pomalidomide (Primary) ; Bortezomib; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms OPTIMISMM
- Sponsors Celgene Corporation
- 10 Jul 2019 Results presented in a Celgene Corporation media release.
- 10 Jul 2019 According to a Celgene Corporation media release, based on this pivotal trial (OPTIMISMM), the Health Canada has approved a POMALYST (pomalidomide)-based triplet combination with bortezomib and dexamethasone. This is a new treatment option for patients with multiple myeloma (MM) who have received at least one prior treatment regimen that included REVLIMID (lenalidomide).
- 16 May 2019 According to a Celgene Corporation media release, the approval of the IMNOVID triplet (PVd) by the European Commission (EC) was supported by data from this study (OPTIMISMM).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History